AstraZeneca sells its vaccine in India under the brand name Covishield. It admitted that its vaccine may, in rare cases, lead to side effects including blood clots.
Representative image
AstraZeneca, which sells its vaccine in India under the brand name Covishield, has admitted that its vaccine may, in rare cases, lead to side effects including blood clots. The UK-based pharmaceutical firm AstraZeneca made the revelation in court documents, reported The Telegraph. It said its Covid-19 vaccine, in rare cases, led to Thrombocytopenia syndrome (TTS).